Monopar Therapeutics (MNPR) EBIAT (2017 - 2019)
Historic EBIAT for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to -$1.2 million.
- Monopar Therapeutics' EBIAT fell 3553.19% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.2 million, marking a year-over-year decrease of 3864.88%. This contributed to the annual value of -$4.2 million for FY2019, which is 3088.49% down from last year.
- As of Q4 2019, Monopar Therapeutics' EBIAT stood at -$1.2 million, which was down 3553.19% from -$736080.0 recorded in Q3 2019.
- Over the past 5 years, Monopar Therapeutics' EBIAT peaked at -$372915.0 during Q1 2017, and registered a low of -$14.9 million during Q3 2017.
- For the 3-year period, Monopar Therapeutics' EBIAT averaged around -$2.0 million, with its median value being -$806213.5 (2018).
- Examining YoY changes over the last 5 years, Monopar Therapeutics' EBIAT showed a top increase of 9569.68% in 2018 and a maximum decrease of 13499.91% in 2018.
- Quarter analysis of 3 years shows Monopar Therapeutics' EBIAT stood at -$713583.0 in 2017, then fell by 24.79% to -$890461.0 in 2018, then plummeted by 35.53% to -$1.2 million in 2019.
- Its last three reported values are -$1.2 million in Q4 2019, -$736080.0 for Q3 2019, and -$905700.0 during Q2 2019.